Multi-gene panel testing in breast cancer management

Christos Fountzilas, Virginia G. Kaklamani

Producción científica: Chapter

22 Citas (Scopus)


Hereditary predisposition accounts for approximately 10% of all breast cancers and is mostly associated with germline mutations in high-penetrance genes encoding for proteins participating in DNA repair through homologous recombination (BRCA1 and BRCA2). With the advent of massive parallel next-generation DNA sequencing, simultaneous analysis of multiple genes with a short turnaround time and at a low cost has become possible. The clinical validity and utility of multi-gene panel testing is getting better characterized as more data on the significance of moderate-penetrance genes are collected from large, cancer genetic testing studies. In this chapter, we attempt to provide a general guide for interpretation of panel gene testing in breast cancer and use of the information obtained for clinical decision-making.

Idioma originalEnglish (US)
Título de la publicación alojadaCancer Treatment and Research
EditorialSpringer International Publishing
Número de páginas20
EstadoPublished - 2018

Serie de la publicación

NombreCancer Treatment and Research
ISSN (versión impresa)0927-3042

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'Multi-gene panel testing in breast cancer management'. En conjunto forman una huella única.

Citar esto